S&P 500   4,270.96 (-0.07%)
DOW   33,876.15 (-0.31%)
QQQ   329.08 (+0.18%)
AAPL   174.07 (-0.27%)
MSFT   290.50 (-0.28%)
META   174.52 (-0.19%)
GOOGL   119.96 (+0.34%)
AMZN   142.02 (-0.06%)
TSLA   912.37 (+0.04%)
NVDA   187.11 (+2.05%)
NIO   19.90 (-0.90%)
BABA   90.49 (+0.80%)
AMD   100.38 (+2.15%)
MU   62.84 (+1.98%)
T   18.42 (+0.00%)
CGC   3.80 (-6.40%)
F   16.00 (-0.19%)
GE   79.31 (-0.76%)
DIS   122.31 (-0.41%)
AMC   20.12 (-5.81%)
PYPL   98.63 (-0.79%)
PFE   48.57 (-1.42%)
NFLX   245.04 (+1.61%)
S&P 500   4,270.96 (-0.07%)
DOW   33,876.15 (-0.31%)
QQQ   329.08 (+0.18%)
AAPL   174.07 (-0.27%)
MSFT   290.50 (-0.28%)
META   174.52 (-0.19%)
GOOGL   119.96 (+0.34%)
AMZN   142.02 (-0.06%)
TSLA   912.37 (+0.04%)
NVDA   187.11 (+2.05%)
NIO   19.90 (-0.90%)
BABA   90.49 (+0.80%)
AMD   100.38 (+2.15%)
MU   62.84 (+1.98%)
T   18.42 (+0.00%)
CGC   3.80 (-6.40%)
F   16.00 (-0.19%)
GE   79.31 (-0.76%)
DIS   122.31 (-0.41%)
AMC   20.12 (-5.81%)
PYPL   98.63 (-0.79%)
PFE   48.57 (-1.42%)
NFLX   245.04 (+1.61%)
S&P 500   4,270.96 (-0.07%)
DOW   33,876.15 (-0.31%)
QQQ   329.08 (+0.18%)
AAPL   174.07 (-0.27%)
MSFT   290.50 (-0.28%)
META   174.52 (-0.19%)
GOOGL   119.96 (+0.34%)
AMZN   142.02 (-0.06%)
TSLA   912.37 (+0.04%)
NVDA   187.11 (+2.05%)
NIO   19.90 (-0.90%)
BABA   90.49 (+0.80%)
AMD   100.38 (+2.15%)
MU   62.84 (+1.98%)
T   18.42 (+0.00%)
CGC   3.80 (-6.40%)
F   16.00 (-0.19%)
GE   79.31 (-0.76%)
DIS   122.31 (-0.41%)
AMC   20.12 (-5.81%)
PYPL   98.63 (-0.79%)
PFE   48.57 (-1.42%)
NFLX   245.04 (+1.61%)
S&P 500   4,270.96 (-0.07%)
DOW   33,876.15 (-0.31%)
QQQ   329.08 (+0.18%)
AAPL   174.07 (-0.27%)
MSFT   290.50 (-0.28%)
META   174.52 (-0.19%)
GOOGL   119.96 (+0.34%)
AMZN   142.02 (-0.06%)
TSLA   912.37 (+0.04%)
NVDA   187.11 (+2.05%)
NIO   19.90 (-0.90%)
BABA   90.49 (+0.80%)
AMD   100.38 (+2.15%)
MU   62.84 (+1.98%)
T   18.42 (+0.00%)
CGC   3.80 (-6.40%)
F   16.00 (-0.19%)
GE   79.31 (-0.76%)
DIS   122.31 (-0.41%)
AMC   20.12 (-5.81%)
PYPL   98.63 (-0.79%)
PFE   48.57 (-1.42%)
NFLX   245.04 (+1.61%)
OTCMKTS:RCPIQ

Rock Creek Pharmaceuticals - RCPIQ Stock Forecast, Price & News

Add
Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
112 shs
Average Volume
80 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
RCPIQ stock logo

About Rock Creek Pharmaceuticals (OTCMKTS:RCPIQ) Stock

Rock Creek Pharmaceuticals, Inc., a pharmaceutical development company, focuses on the discovery, development, and commercialization of therapies for chronic inflammatory disease and neurologic disorders. Its lead compound is Anatabine citrate, a small molecule, cholinergic agonist, which exhibits anti-inflammatory pharmacological characteristics, with a mechanism of action distinct from other anti-inflammatory drugs available, such as biologics, steroids, and non-steroidal anti-inflammatories. The company was formerly known as Star Scientific, Inc. and changed its name to Rock Creek Pharmaceuticals, Inc. in June 2014. Rock Creek Pharmaceuticals, Inc. is headquartered in Sarasota, Florida. On September 27, 2016, Rock Creek Pharmaceuticals, Inc., along with its affiliates, filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Delaware.

Receive RCPIQ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rock Creek Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RCPIQ Stock News Headlines

North Rock Creek wins twice over Harrah
North Rock Creek band makes history
McLoud boys trip North Rock Creek
North Rock Creek squads top Seminole
See More Headlines

Receive RCPIQ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rock Creek Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RCPIQ Company Calendar

Today
8/18/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Medicinals & botanicals
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:RCPIQ
Previous Symbol
NASDAQ:RCPI
Employees
5
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
1.83

Key Executives

  • Dr. Michael John Mullan MBBS (M.D. (Age 65)
    ), Ph.D., Chairman, Chief Exec. Officer and Pres
    Comp: $658.99k
  • Dr. Curtis Wright IV (Age 73)
    Sr. VP and Medical & Clinical Director













RCPIQ Stock - Frequently Asked Questions

Are investors shorting Rock Creek Pharmaceuticals?

Rock Creek Pharmaceuticals saw a decrease in short interest during the month of July. As of July 15th, there was short interest totaling 6,900 shares, a decrease of 85.4% from the June 30th total of 47,200 shares. Based on an average daily trading volume, of 8,100 shares, the short-interest ratio is currently 0.9 days.
View Rock Creek Pharmaceuticals' Short Interest
.

What is Rock Creek Pharmaceuticals' stock symbol?

Rock Creek Pharmaceuticals trades on the OTCMKTS under the ticker symbol "RCPIQ."

How do I buy shares of Rock Creek Pharmaceuticals?

Shares of RCPIQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

How can I contact Rock Creek Pharmaceuticals?

Rock Creek Pharmaceuticals' mailing address is 2040 WHITFIELD AVE. SUITE 300, SARASOTA FL, 34243. The official website for the company is www.rockcreekpharmaceuticals.com. The company can be reached via phone at (844) 727-0727, via email at tjenkins@rockcreekpharmaceuticals.com, or via fax at 302-636-5454.

This page (OTCMKTS:RCPIQ) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.